---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-065895"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-11-22T23:59:59+00:00"
generated_at: "2026-06-07T22:21:33.276474+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics shareholders approve increase in authorized common stock and preferred stock conversion

## Summary
- Shareholders approved amendment to increase authorized common stock from 490M to 800M shares on Nov 22, 2023.
- Proposal 1 received 40,768,042 votes for, 1,732,365 against, and 375,532 abstentions.
- Shareholders also approved potential issuance >19.99% of outstanding common stock upon conversion of Series A Preferred Stock.
- Proposal 2 received 33,420,475 votes for, 352,390 against, 376,812 abstentions, and 8,726,262 broker non-votes.
- The conversion involves Series A-1, A-2, and A-3 Convertible Preferred Stock under Nasdaq rules.

## SEC filing metadata
- accession: 0000950170-23-065895
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-11-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017023065895/0000950170-23-065895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017023065895/sabs-20231122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-065895
- JSON: https://secwatch.observer/filing/0000950170-23-065895.json
- Plain text: https://secwatch.observer/filing/0000950170-23-065895.txt

## Key facts
- Governance Changes
  SAB Biotherapeutics, Inc.: Increased authorized shares of common stock from 490,000,000 to 800,000,000 (effective 2023-11-22).
  - Change: charter amendment
  - Effective: 2023-11-22
  source text: On November 22, 2023, the Company held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock, par value $0.0001 per share (the “Common Stock”) from 490,000,000 shares to 800,000,000 shares. The increase in the authorized number of shares of the Common Stock was effected pursuant to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on November 22, 2023 and was effective as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017023065895/0000950170-23-065895-index.htm
- Shareholder Votes
  SAB Biotherapeutics, Inc. shareholders approved Amendment to increase authorized shares from 490,000,000 to 800,000,000.
  - Proposal: charter amendment
  - Outcome: passed
  source text: Proposal 1. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of Common Stock authorized for issuance from 490,000,000 shares to 800,000,000 shares. The voting results were as follows: Votes For Votes Against Abstentions 40,768,042 1,732,365 375,532
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017023065895/0000950170-23-065895-index.htm
- Shareholder Votes
  SAB Biotherapeutics, Inc. shareholders approved Potential issuance in excess of 19.99% of outstanding Common Stock upon conversion of Series A Preferred Stock.
  - Outcome: passed
  source text: Proposal 2 . Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding Common Stock upon the conversion of the Company’s Series A-1 Convertible Preferred Stock, par value $0.0001 per share (the “Series A-1 Preferred Stock”), Series A-2 Convertible Preferred Stock, par value $0.0001 per share (the “Series A-2 Preferred Stock”), and Series A-3 Convertible Preferred Stock, par value $0.0001 per share (the “Series A-3 Preferred Stock” and, together with the Series A-1 Preferred Stock and Series A-2 Preferred Stock, the “Series A Preferred Stock”) at less than the “minimum price” under Nasdaq Listing Rule 5635(d), and which may deemed a “change of control” under Nasdaq Listing Rule 5635, pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock governing the Series A Preferred Stock. The voting results were as follows: Votes For Votes Against Abstentions Broker Non Votes 3
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017023065895/0000950170-23-065895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.